ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

CNTB vs XLO // GROSS PROFIT MARGIN

Connect Biopharma Holdings Limited (NASDAQ) VS. Xilio Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: CNTB 1 — XLO 3
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CNTB VS. XLO) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC CNTB XLO SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin ACTIVE — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — -10.78% — TIE /fcf-yield <GO>
Operating Margin -60.00% -60.00% 0.00 TIE /operating-margins <GO>
Net Profit Margin -60.00% -60.00% 0.00 TIE /net-margins <GO>
Revenue Growth (YoY) -65.00% 180.00% -245.00 XLO /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 0.20 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 4/9 -2.00 XLO /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 33.2 42.1 -8.88 XLO /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $52.6M $51.1M $1.5M CNTB /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR CNTB REV XLO REV CNTB GROSS % XLO GROSS % CNTB FCF XLO FCF
FY 2025 $64.0K $43.8M — — -$51.6M -$5.5M
FY 2024 $26.0M $6.3M — — -$24.4M -$18.4M
FY 2023 $0 $0 — — -$47.7M -$68.6M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CNTB // BETA —
XLO // BETA —